AbbVie (ABBV) Gets FDA Nod for Another Botox Label Expansion

AbbVie (ABBV) wins the FDA nod for an expanded use of Botox to treat spasticity in pediatric patients aged two years and above including those with lower limb spasticity caused by cerebral palsy.
( read original story …)


Advertisement